ParkinsonFranceV1, Main, Exploration, bibRecordById, pubmed:8649546

Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease

Identifieur interne : 004665 ( Main/Exploration ); précédent : 004664; suivant : 004666

Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease

Auteurs : A. F. Carpentier [France] ; A. M. Bonnet [France] ; M. Vidailhet [France] ; Yves Agid [France]

Source :

Neurology [ 0028-3878 ] ; 1996.

RBID : Pascal:96-0309011

Descripteurs français

Pascal (Inist)
- Parkinson maladie, Dyskinésie, Lévodopa, Antiparkinsonien, Propranolol, Bloquant β-adrénergique, Antagoniste, Traitement, Homme, Récepteur β-adrénergique, Chimiothérapie, Dose faible, Traitement adjuvant.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Adjuvant treatment, Adrenergic beta-Antagonists (therapeutic use), Adult, Antagonist, Antiparkinson Agents (adverse effects), Antiparkinson Agents (therapeutic use), Antiparkinson agent, Beta blocking agent, Chemotherapy, Dyskinesia, Female, Human, Humans, Levodopa, Levodopa (adverse effects), Levodopa (therapeutic use), Low dose, Male, Movement Disorders (drug therapy), Movement Disorders (etiology), Parkinson Disease (drug therapy), Parkinson disease, Propranolol (therapeutic use), Prospective Studies, Treatment, Treatment Outcome, β-Adrenergic receptor.
MESH :
- chemical , adverse effects : Antiparkinson Agents, Levodopa.
- chemical , therapeutic use : Adrenergic beta-Antagonists, Antiparkinson Agents, Levodopa, Propranolol.
- drug therapy : Movement Disorders, Parkinson Disease.
- etiology : Movement Disorders.
- Adult, Female, Humans, Male, Prospective Studies, Treatment Outcome.

Abstract

Seven patients suffering from Parkinson's disease (PD) with severely disabling dyskinesia received low-dose propranolol as an adjunct to the currently used medical treatment. There was a significant 40% improvement in the dyskinesia score without increase of parkinsonian motor disability. Ballistic and choreic dyskinesia were markedly ameliorated, whereas dystonia was not. This study suggests that administration of low doses of beta-blockers may improve levodopa-induced ballistic and choreic dyskinesia in PD.

Affiliations:

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease</title>
<author><name sortKey="Carpentier, A F" sort="Carpentier, A F" uniqKey="Carpentier A" first="A. F." last="Carpentier">A. F. Carpentier</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Fédération de Neurologie and INSERM U289, Hôpital de la Salpétrière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bonnet, A M" sort="Bonnet, A M" uniqKey="Bonnet A" first="A. M." last="Bonnet">A. M. Bonnet</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Fédération de Neurologie and INSERM U289, Hôpital de la Salpétrière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Vidailhet, M" sort="Vidailhet, M" uniqKey="Vidailhet M" first="M." last="Vidailhet">M. Vidailhet</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Fédération de Neurologie and INSERM U289, Hôpital de la Salpétrière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Agid, Y" sort="Agid, Y" uniqKey="Agid Y" first="Y." last="Agid">Yves Agid</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Fédération de Neurologie and INSERM U289, Hôpital de la Salpétrière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
<placeName><settlement type="city">Paris</settlement>
<region type="region" nuts="2">Île-de-France</region>
</placeName>
<orgName type="hospital" n="4">Hôpital de la Salpêtrière</orgName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">96-0309011</idno>
<date when="1996">1996</date>
<idno type="stanalyst">PASCAL 96-0309011 INIST</idno>
<idno type="RBID">Pascal:96-0309011</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001802</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001844</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001649</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">001649</idno>
<idno type="wicri:doubleKey">0028-3878:1996:Carpentier A:improvement:of:levodopa</idno>
<idno type="wicri:Area/Main/Merge">004F45</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:8649546</idno>
<idno type="wicri:Area/PubMed/Corpus">001578</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001578</idno>
<idno type="wicri:Area/PubMed/Curation">001537</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001537</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001537</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001537</idno>
<idno type="wicri:Area/Ncbi/Merge">001E03</idno>
<idno type="wicri:Area/Ncbi/Curation">001E03</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001E03</idno>
<idno type="wicri:doubleKey">0028-3878:1996:Carpentier A:improvement:of:levodopa</idno>
<idno type="wicri:Area/Main/Merge">004D37</idno>
<idno type="wicri:Area/Main/Curation">004665</idno>
<idno type="wicri:Area/Main/Exploration">004665</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease</title>
<author><name sortKey="Carpentier, A F" sort="Carpentier, A F" uniqKey="Carpentier A" first="A. F." last="Carpentier">A. F. Carpentier</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Fédération de Neurologie and INSERM U289, Hôpital de la Salpétrière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bonnet, A M" sort="Bonnet, A M" uniqKey="Bonnet A" first="A. M." last="Bonnet">A. M. Bonnet</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Fédération de Neurologie and INSERM U289, Hôpital de la Salpétrière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Vidailhet, M" sort="Vidailhet, M" uniqKey="Vidailhet M" first="M." last="Vidailhet">M. Vidailhet</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Fédération de Neurologie and INSERM U289, Hôpital de la Salpétrière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Agid, Y" sort="Agid, Y" uniqKey="Agid Y" first="Y." last="Agid">Yves Agid</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Fédération de Neurologie and INSERM U289, Hôpital de la Salpétrière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
<placeName><settlement type="city">Paris</settlement>
<region type="region" nuts="2">Île-de-France</region>
</placeName>
<orgName type="hospital" n="4">Hôpital de la Salpêtrière</orgName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Neurology</title>
<title level="j" type="abbreviated">Neurology</title>
<idno type="ISSN">0028-3878</idno>
<imprint><date when="1996">1996</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Neurology</title>
<title level="j" type="abbreviated">Neurology</title>
<idno type="ISSN">0028-3878</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjuvant treatment</term>
<term>Adrenergic beta-Antagonists (therapeutic use)</term>
<term>Adult</term>
<term>Antagonist</term>
<term>Antiparkinson Agents (adverse effects)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Antiparkinson agent</term>
<term>Beta blocking agent</term>
<term>Chemotherapy</term>
<term>Dyskinesia</term>
<term>Female</term>
<term>Human</term>
<term>Humans</term>
<term>Levodopa</term>
<term>Levodopa (adverse effects)</term>
<term>Levodopa (therapeutic use)</term>
<term>Low dose</term>
<term>Male</term>
<term>Movement Disorders (drug therapy)</term>
<term>Movement Disorders (etiology)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson disease</term>
<term>Propranolol (therapeutic use)</term>
<term>Prospective Studies</term>
<term>Treatment</term>
<term>Treatment Outcome</term>
<term>β-Adrenergic receptor</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Adrenergic beta-Antagonists</term>
<term>Antiparkinson Agents</term>
<term>Levodopa</term>
<term>Propranolol</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Movement Disorders</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Movement Disorders</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Prospective Studies</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Dyskinésie</term>
<term>Lévodopa</term>
<term>Antiparkinsonien</term>
<term>Propranolol</term>
<term>Bloquant β-adrénergique</term>
<term>Antagoniste</term>
<term>Traitement</term>
<term>Homme</term>
<term>Récepteur β-adrénergique</term>
<term>Chimiothérapie</term>
<term>Dose faible</term>
<term>Traitement adjuvant</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Seven patients suffering from Parkinson's disease (PD) with severely disabling dyskinesia received low-dose propranolol as an adjunct to the currently used medical treatment. There was a significant 40% improvement in the dyskinesia score without increase of parkinsonian motor disability. Ballistic and choreic dyskinesia were markedly ameliorated, whereas dystonia was not. This study suggests that administration of low doses of beta-blockers may improve levodopa-induced ballistic and choreic dyskinesia in PD.</div>
</front>
</TEI>
<affiliations><list><country><li>France</li>
</country>
<region><li>Île-de-France</li>
</region>
<settlement><li>Paris</li>
</settlement>
<orgName><li>Hôpital de la Salpêtrière</li>
</orgName>
</list>
<tree><country name="France"><region name="Île-de-France"><name sortKey="Carpentier, A F" sort="Carpentier, A F" uniqKey="Carpentier A" first="A. F." last="Carpentier">A. F. Carpentier</name>
</region>
<name sortKey="Agid, Y" sort="Agid, Y" uniqKey="Agid Y" first="Y." last="Agid">Yves Agid</name>
<name sortKey="Bonnet, A M" sort="Bonnet, A M" uniqKey="Bonnet A" first="A. M." last="Bonnet">A. M. Bonnet</name>
<name sortKey="Vidailhet, M" sort="Vidailhet, M" uniqKey="Vidailhet M" first="M." last="Vidailhet">M. Vidailhet</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004665 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004665 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:96-0309011
   |texte=   Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease
}}

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024

La maladie de Parkinson en France (serveur d'exploration)

Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease

Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	La maladie de Parkinson en France (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.